Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDX-102
- Development stage
- Preclinical
- Lead developer
- VesiCURE Therapeutics
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
MDX-102 is an exosome-based therapeutic developed by VesiCURE Therapeutics using its proprietary modEXO technology. It is being investigated as an antineoplastic agent for the treatment of solid tumors. The precise mechanism of action has not been defined or disclosed publicly, but it falls under the category of exosome therapies, which typically involve engineered extracellular vesicles designed to deliver therapeutic payloads to target cells. As of the latest updates, MDX-102 remains in preclinical development and has not yet entered clinical trials[1][2].
- Other names
- MDX 102MDX102MDX-102
Beyond the preview
Go deeper on MDX-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDX-102.